Filing Details

Accession Number:
0000921895-20-003088
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-20 20:02:43
Reporting Period:
2020-11-18
Accepted Time:
2020-11-20 20:02:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1750284 Olema Pharmaceuticals Inc. OLMA Investment Advice (6282) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
918923 P L Fund Value Biotechnology 44 Montgomery Street
40Th Fl
San Francisco CA 94104
No No No Yes
1055947 P/il L Partners Bvf 44 Montgomery St.
40Th Floor
San Francisco CA 94104
Yes No Yes No
1056807 Bvf Inc/il 44 Montgomery Street
40Th Fl
San Francisco CA 94104
No No Yes No
1102444 Biotechnology Value Fund Ii Lp 44 Montgomery Street
40Th Fl
San Francisco CA 94104
No No No Yes
1233840 N Mark Lampert 1 Sansome St
30Th Fl
San Francisco CA 94104
No No Yes No
1660683 Biotechnology Value Trading Fund Os Lp P.o. Box 309 Ugland House
Grand Cayman E9 KY1-1104
No No No Yes
1660684 Ltd. Os Partners Bvf P.o. Box 309 Ugland House
Grand Cayman E9 KY1-1104
No No No Yes
1803805 Bvf I Gp Llc 44 Montgomery St., 40Th Floor
San Francisco CA 94104
No No No Yes
1803806 Bvf Ii Gp Llc 44 Montgomery St., 40Th Floor
San Francisco CA 94104
No No No Yes
1803809 Bvf Gp Holdings Llc 44 Montgomery St., 40Th Floor
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 1,129,404 $0.00 1,129,404 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 889,186 $0.00 2,018,590 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 760,155 $0.00 2,778,745 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 613,918 $19.00 3,392,663 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 881,156 $0.00 881,156 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 673,281 $0.00 1,554,437 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 522,403 $0.00 2,076,840 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 446,425 $19.00 2,523,265 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 185,908 $0.00 185,908 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 101,784 $0.00 287,692 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 73,399 $0.00 361,091 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-19 74,991 $19.00 436,082 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, $0.0001 Par Value Stock Option (Right to buy) Acquisiton 2020-11-18 21,520 $0.00 21,520 $19.00
Common Stock, $0.0001 Par Value Stock Option (Right to buy) Acquisiton 2020-11-18 21,520 $0.00 21,520 $19.00
Common Stock, $0.0001 Par Value Stock Option (Right to buy) Acquisiton 2020-11-18 21,520 $0.00 21,520 $19.00
Common Stock, $0.0001 Par Value Series A-1 Convertible Preferred Stock Disposition 2020-11-19 1,129,404 $0.00 1,129,404 $0.00
Common Stock, $0.0001 Par Value Series A-1 Convertible Preferred Stock Disposition 2020-11-19 881,156 $0.00 881,156 $0.00
Common Stock, $0.0001 Par Value Series A-1 Convertible Preferred Stock Disposition 2020-11-19 185,908 $0.00 185,908 $0.00
Common Stock, $0.0001 Par Value Series B Convertible Preferred Stock Disposition 2020-11-19 889,186 $0.00 889,186 $0.00
Common Stock, $0.0001 Par Value Series B Convertible Preferred Stock Disposition 2020-11-19 673,281 $0.00 673,281 $0.00
Common Stock, $0.0001 Par Value Series B Convertible Preferred Stock Disposition 2020-11-19 101,784 $0.00 101,784 $0.00
Common Stock, $0.0001 Par Value Series C Convertible Preferred Stock Disposition 2020-11-19 760,155 $0.00 760,155 $0.00
Common Stock, $0.0001 Par Value Series C Convertible Preferred Stock Disposition 2020-11-19 522,403 $0.00 522,403 $0.00
Common Stock, $0.0001 Par Value Series C Convertible Preferred Stock Disposition 2020-11-19 73,399 $0.00 73,399 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
21,520 2030-11-17 No 4 A Indirect
21,520 2030-11-17 No 4 A Indirect
21,520 2030-11-17 No 4 A Indirect
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
  3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
  4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
  5. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
  6. The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Mr. Hrustanovic's continuous service on the Issuer's board of directors through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Mr. Hrustanovic's continuous service through such vesting date.
  7. The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to Mr. Hrustanovic's continuous service on the Issuer's board of directors through each applicable vesting date.
  8. Effective upon the closing of the Issuer's initial public offering (the "IPO") on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series A-1 Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such shares of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date.
  9. Effective upon the closing of the IPO on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series Series B Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such share of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date.
  10. Effective upon the closing of the IPO on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series C Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such share of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date.